DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.328
EU - Europa 6.304
AS - Asia 3.693
SA - Sud America 523
AF - Africa 73
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 7
Totale 21.956
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.997
PL - Polonia 1.712
CN - Cina 1.634
RU - Federazione Russa 1.323
IT - Italia 1.053
SG - Singapore 1.015
DE - Germania 556
BR - Brasile 446
GB - Regno Unito 365
UA - Ucraina 334
HK - Hong Kong 326
CA - Canada 289
SE - Svezia 256
FR - Francia 234
VN - Vietnam 178
FI - Finlandia 168
KR - Corea 151
TR - Turchia 130
IE - Irlanda 87
IN - India 65
JP - Giappone 47
BE - Belgio 39
NL - Olanda 38
AR - Argentina 34
BD - Bangladesh 29
ZA - Sudafrica 28
EU - Europa 27
MX - Messico 27
AT - Austria 22
ES - Italia 22
CZ - Repubblica Ceca 15
EC - Ecuador 13
LT - Lituania 13
AE - Emirati Arabi Uniti 12
IQ - Iraq 11
KE - Kenya 11
RO - Romania 11
IR - Iran 10
TW - Taiwan 10
CH - Svizzera 8
CO - Colombia 8
ID - Indonesia 8
PK - Pakistan 8
RS - Serbia 8
TN - Tunisia 8
DK - Danimarca 7
JO - Giordania 7
PE - Perù 7
PY - Paraguay 7
UZ - Uzbekistan 7
LB - Libano 6
SA - Arabia Saudita 6
VE - Venezuela 6
AM - Armenia 5
AU - Australia 5
DZ - Algeria 5
EG - Egitto 5
IL - Israele 5
MA - Marocco 5
AL - Albania 4
AZ - Azerbaigian 4
BG - Bulgaria 4
HR - Croazia 4
DO - Repubblica Dominicana 3
GR - Grecia 3
HU - Ungheria 3
LV - Lettonia 3
NO - Norvegia 3
PH - Filippine 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GE - Georgia 2
KH - Cambogia 2
NI - Nicaragua 2
NP - Nepal 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GD - Grenada 1
HN - Honduras 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ME - Montenegro 1
MM - Myanmar 1
MQ - Martinica 1
MU - Mauritius 1
MW - Malawi 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
Totale 21.945
Salva come PNG Salva come JPEG
Città #
Warsaw 1.486
Fairfield 1.295
Woodbridge 971
Ashburn 946
Jacksonville 793
Houston 622
Chandler 567
Seattle 538
Wilmington 514
Ann Arbor 483
Cambridge 449
Singapore 438
Dallas 352
Boardman 351
Hong Kong 312
Beijing 269
Camerino 259
Nanjing 244
Kraków 213
Toronto 199
Los Angeles 177
The Dalles 137
Seoul 127
New York 117
San Mateo 117
Tongling 116
Dearborn 111
Lawrence 111
Princeton 111
Columbus 107
London 104
Istanbul 103
Moscow 91
Ogden 89
Dublin 85
Düsseldorf 81
San Diego 73
Nanchang 71
Buffalo 69
Shanghai 68
Chicago 66
Council Bluffs 65
Helsinki 65
Milan 60
Lachine 57
São Paulo 56
Guangzhou 54
Ho Chi Minh City 52
Munich 51
Dong Ket 49
Tianjin 48
Kunming 46
Shenyang 43
Brussels 39
Jiaxing 38
Hebei 36
Centro 34
Tokyo 34
Rome 32
Santa Clara 31
Changsha 26
Denver 25
Frankfurt am Main 25
Hangzhou 25
Atlanta 24
Philadelphia 24
San Francisco 24
Hanoi 23
Jinan 23
Wuhan 23
Falls Church 22
Orem 22
Phoenix 22
Poplar 22
Redwood City 22
San Jose 22
Hefei 20
Ningbo 20
Norwalk 20
Redondo Beach 20
Scafati 20
Boston 18
Chennai 17
Brooklyn 16
Jinhua 16
Johannesburg 16
Manchester 16
Montreal 16
Nuremberg 16
Stockholm 16
Turku 16
Verona 16
Zhengzhou 16
Bologna 15
Rio de Janeiro 15
Venezia 15
Salt Lake City 14
Tampa 13
Ancona 12
Nürnberg 12
Totale 15.087
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 621
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 405
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 384
Overview on Radiolabel-Free in Vitro Assays for GPCRs 379
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 355
Pharmacological characterization of the GPR17 receptor dual profile 355
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 342
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 341
The G Protein-Coupled Receptor GPR17: Overview and Update 327
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 326
Emerging Roles of Purinergic Signaling in Diabetes 323
GPR17 receptor modulators and their therapeutic implications: review of recent patents 281
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 277
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 273
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 271
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 269
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 262
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 252
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 252
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 249
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 248
P2X7 Receptor as a Therapeutic Target 244
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 237
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 229
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 227
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 222
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 217
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 214
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 214
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 212
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 212
New sensible method to quantize the intestinal absorption of receptor ligands 210
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 208
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 206
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 205
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 203
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 202
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 201
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 200
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 200
Antiviral properties of deazaadenine nucleoside derivatives 200
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 200
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 198
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 196
Interaction model for anthracycline activity against DNA topoisomerase II 196
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 195
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 193
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 192
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 191
Adenosine receptor modeling: what does the A2A crystal structure tell us? 189
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 189
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 189
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 187
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 186
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 185
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 184
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 181
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 180
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 180
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 177
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 177
The P2X7 Receptor in Infection and Inflammation 177
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 176
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 173
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 173
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 170
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 168
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 166
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 165
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 164
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 163
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 161
I protocolli operativi nella violenza di genere 157
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 156
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 155
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 154
Development of novel pyridazinone-based adenosine receptor ligands 151
Rational design of new competitive inhibitors of human CK2 activity 147
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 145
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 143
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 142
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 140
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 140
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 139
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 138
Substituted adenine derivatives as novel P2X3 receptor ligands 135
null 134
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 132
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 129
New purine derivatives as P2X3 receptor antagonists 129
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 129
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 128
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 126
Letters in Drug Design & Discovery 124
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 121
Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies 119
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 118
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 118
Toward the rational design of Protein Kinase CK2 inhibitors 115
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 114
Totale 20.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.706
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.706
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.362 0 0 0 0 0 450 666 100 299 222 369 256
2021/20221.488 184 371 33 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/20241.247 161 64 80 49 57 114 65 92 138 44 45 338
2024/20254.107 180 74 330 195 135 258 476 1.025 340 283 277 534
2025/20263.195 367 349 702 813 641 323 0 0 0 0 0 0
Totale 22.368